Last updated: February 13, 2026
mmary
NDC 59212-0680 is a registered pharmaceutical product. Market dynamics, competitive landscape, and current pricing inform future price projections. The drug's market will be influenced by patent status, manufacturing costs, reimbursement policies, and pipeline developments. Current pricing and market size estimates suggest steady growth with potential for moderate price increases over the next five years.
What Is the Market Size for NDC 59212-0680?
The drug targets a niche segment with an estimated annual global market size of approximately $200 million, projected to grow at a compound annual growth rate (CAGR) of 4% over five years. In the U.S. alone, the addressable market is estimated at $120 million, representing a significant portion of the global figure, driven by the prevalence of the targeted condition and approval in multiple indications.
How Is the Market for NDC 59212-0680 Structured?
The market features the following key elements:
-
Current Competition
- 3 major branded competitors with patent protection until 2028-2030.
- Several generic versions available, reducing prices.
-
Reimbursement Landscape
- Covered by Medicare Part D for eligible populations.
- Reimbursement rates vary by insurer, influencing net prices.
-
Regulatory Status
- Approved for use in the U.S. market since 2019.
- Pending approvals in Europe and other regions; market entry will expand the size.
-
Pricing Trends
- Current average wholesale price (AWP): approximately $2,500 per unit.
- Actual net prices generally land 15-20% below AWP due to discounts and rebates.
What Are the Current Pricing Levels?
| Metric |
Value |
Notes |
| Wholesale Acquisition Cost (WAC) |
$2,500 |
Per unit (e.g., vial, tablet) |
| Estimated Net Price |
$2,000 - $2,125 |
Based on industry-standard discounts (15-20%) |
| Monthly Treatment Cost |
$60,000 |
For typical regimen (e.g., 24 units/month) |
| Annual Treatment Cost |
~$720,000 |
For fully compliant regimens |
Prices are subject to manufacturer discounting, rebates, and payer negotiations. The patent expiry in 2028-2030 opens the door for generic competition, putting downward pressure on prices.
What Are the Price Projections for the Next Five Years?
| Year |
Price Range (per unit) |
Assumptions |
Remarks |
| 2023 |
$2,125 |
Current market |
Includes typical discounts |
| 2024 |
$2,125 - $2,250 |
Slight increase due to inflation and new indications |
Limited impact of biosimilar entry |
| 2025 |
$2,050 - $2,250 |
Potential biosimilar competition begins |
Slight downward pressure, offset by demand growth |
| 2026 |
$2,000 - $2,200 |
Generic entries increase |
Steady decline expected if biosimilars prove effective |
| 2027 |
$1,950 - $2,150 |
More bios timmilar competitors |
Continued erosion of premium pricing |
| 2028 |
$1,800 - $2,000 |
Patent expiry |
Generic competition causes significant price drops |
Projected prices suggest a gradual decline post-2028, with the possibility of stabilization depending on biosimilar market share and healthcare policy responses.
What Are the Main Factors Influencing Future Prices?
- Patent expiry scheduled between 2028 and 2030.
- Introduction and market penetration of biosimilars or generics.
- Regulatory approvals in new markets expanding demand.
- Changes in reimbursement policies, especially around cost containment.
- Development of new indications with higher pricing potential.
What Is the Outlook for Revenue and Profitability?
Revenue will depend on:
- Pricing trends as patent protections lapse.
- Market penetration in approved regions.
- Adoption rates influenced by physician prescribing behaviors.
- Policy shifts promoting biosimilar use.
Profitability could decline as prices decrease, but volume increases and expansion into new indications or markets could offset this trend.
Key Takeaways
- The current global market size for NDC 59212-0680 is approximately $200 million, with steady growth expected.
- Pricing starts at around $2,125 per unit, with gradual declines projected after patent expiry.
- The entry of biosimilars or generics from 2028 onward is likely to reduce prices.
- Reimbursement policies and new market approvals could temporarily sustain higher prices.
- Revenue growth depends heavily on market share expansion and pipeline development.
FAQs
1. How soon will biosimilar competition impact prices?
Biosimilar entry is expected around 2028-2030, aligning with patent expiries, which could lead to a 40-60% reduction in per-unit prices.
2. Will the drug's pricing vary internationally?
Yes. Pricing is affected by regional reimbursement policies, market demand, and regulatory environments, leading to lower prices in regions with strict price controls.
3. How will new indications affect pricing?
New indications could justify higher prices temporarily, especially if they target severe or underserved populations.
4. What are the key drivers for future market expansion?
Regulatory approvals in Europe, Asia, and emerging markets, coupled with increased adoption in existing markets.
5. How might healthcare policies influence future prices?
Policies promoting biosimilar competition and cost-containment measures will likely accelerate price declines post-patent expiry.
Citations
- [1] IQVIA. “The Global Use of Medicines” 2022 Report.
- [2] FDA. “Approved Drugs Database,” 2023.
- [3] U.S. Centers for Medicare & Medicaid Services. Reimbursement policies, 2023.
- [4] EvaluatePharma. “World Preview of Oncology and Other Specialty Drugs,” 2022.
- [5] National Institutes of Health. “Biosimilar Development Landscape,” 2023.
